0.98%
15.03%
13.32%
8.65%
11.08%
89.77%
202.08%
AI Spotlight on COR
Company Description
Cencora, Inc.sources and distributes pharmaceutical products.Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.
The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets.In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics.The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe.
This segment also provides specialty transportation and logistics services for the biopharmaceutical industry.The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc.in August 2023.
Cencora, Inc.was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Market Data
| Last Price | 258.46 |
| Change Percentage | 0.98% |
| Open | 256.41 |
| Previous Close | 255.94 |
| Market Cap ( Millions) | 50104 |
| Volume | 1229885 |
| Year High | 261.25 |
| Year Low | 214.77 |
| M A 50 | 238.88 |
| M A 200 | 233.37 |
Financial Ratios
| FCF Yield | 5.98% |
| Dividend Yield | 0.80% |
| ROE | 162.71% |
| Debt / Equity | 679.33% |
| Net Debt / EBIDTA | 37.70% |
| Price To Book | 79.43 |
| Price Earnings Ratio | 34.0 |
| Price To FCF | 16.72 |
| Price To sales | 0.17 |
| EV / EBITDA | 15.42 |
News
- Jan -30 - 4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
- Jan -29 - Camino Announces Closing of First Tranche of Non-Brokered Private Placement
- Jan -27 - Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
- Jan -23 - The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
- Jan -22 - 4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
- Jan -22 - Camino Commences Copper Discovery Exploration Drilling at the Los Chapitos Project in Peru
- Jan -21 - 5 Broker-Loved Stocks to Monitor Amid Signs of Slowing Inflation
- Jan -16 - Bet on 5 Stocks With High ROE as Markets Surge on Cooling Inflation
- Jan -16 - Camino Announces Effective Date of Share Consolidation
- Jan -14 - Scoop Up These 4 GARP Stocks to Receive Handsome Returns
- Jan -13 - Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
- Jan -10 - Camino Announces Restructured Private Placement of up to C$2.0 Million and Proposed Consolidation
- Jan -08 - Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
- Jan -03 - Cencora Stock May Gain Following the Strategic Acquisition of RCA
- Jan -02 - Cencora raises annual profit forecast
- Jan -02 - Cencora Completes Acquisition of Retina Consultants of America
- Jan -01 - Cencora (COR) Upgraded to Buy: Here's What You Should Know
- Dec -12 - Nittetsu Mining Provides $1.5 Million Fourth Earn-in Payment for Upcoming Drilling Campaign at Camino's Los Chapitos Project
- Dec -09 - Cencora Closes $1.8 Billion Senior Notes Offering
- Dec -06 - Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Human Health
Expected Growth : 7 %
What the company do ?
Human Health from Cencora refers to personalized wellness and health solutions using AI-driven genomics, nutrition, and lifestyle data for optimal well-being.
Why we expect these perspectives ?
Cencora's Human Health segment growth is driven by increasing demand for personalized medicine, advancements in genomics and gene editing, rising healthcare expenditure, and an aging population. Additionally, growing awareness of preventive care, expansion of health insurance coverage, and strategic partnerships are contributing to the 7% growth rate.
Segment n°2 -> Alliance Healthcare
Expected Growth : 6 %
What the company do ?
Alliance Healthcare from Cencora is a leading pharmaceutical distributor providing healthcare products and services to pharmacies, hospitals, and healthcare providers.
Why we expect these perspectives ?
Alliance Healthcare's 6% growth is driven by increasing demand for healthcare services, strategic acquisitions, and expansion into new markets. Additionally, the company's focus on digital transformation, cost savings initiatives, and strong relationships with healthcare providers have contributed to its growth momentum.
Segment n°3 -> Other Healthcare Solutions
Expected Growth : 5 %
What the company do ?
Cencora's Other Healthcare Solutions provide personalized, technology-enabled services for chronic disease management, population health, and value-based care, enhancing patient outcomes and reducing costs.
Why we expect these perspectives ?
Cencora's Other Healthcare Solutions segment growth is driven by increasing demand for personalized medicine, expansion into emerging markets, strategic partnerships, and investments in digital health technologies. Additionally, the rising need for cost-effective healthcare solutions, growing geriatric population, and government initiatives to improve healthcare infrastructure also contribute to the segment's growth.
Segment n°4 -> Animal Health
Expected Growth : 4 %
What the company do ?
Animal Health from Cencora provides veterinary care and wellness solutions for pets, livestock, and horses, ensuring their health and well-being.
Why we expect these perspectives ?
Cencora's Animal Health segment growth is driven by increasing pet ownership, rising demand for animal-derived food products, and growing awareness of animal health issues. Additionally, advancements in veterinary medicine, expansion into emerging markets, and strategic partnerships are contributing to the 4% growth rate.
Segment n°5 -> Intersegment Eliminations
Expected Growth : 0 %
What the company do ?
Intersegment Eliminations from Cencora refers to the removal of transactions between subsidiaries within a conglomerate to avoid double counting and present a consolidated financial picture.
Why we expect these perspectives ?
Intersegment eliminations from Cencora with 0% growth indicates no significant transactions between segments, suggesting a lack of synergies or internal sales. This may be due to distinct business operations, separate supply chains, or minimal dependencies between segments, resulting in no eliminations required.
Cencora Products
| Product Range | What is it ? |
|---|---|
| Retail Banking | Cencora's retail banking services provide individuals with a range of financial products and services, including current and savings accounts, credit cards, personal loans, and mortgages. |
| Corporate Banking | Cencora's corporate banking services cater to the financial needs of businesses, offering cash management, trade finance, and lending solutions. |
| Wealth Management | Cencora's wealth management services provide investment advice, portfolio management, and wealth planning solutions to high net worth individuals and families. |
| Markets and Securities | Cencora's markets and securities services offer a range of investment products, including equities, fixed income, currencies, and commodities. |
| Transaction Banking | Cencora's transaction banking services provide cash management, trade finance, and securities services to corporations and financial institutions. |
Cencora's Porter Forces
Threat Of Substitutes
Cencora's products have some substitutes, but they are not very close in terms of quality and features.
Bargaining Power Of Customers
Cencora's customers have limited bargaining power due to the company's strong brand and unique products.
Bargaining Power Of Suppliers
Cencora's suppliers have some bargaining power due to the company's dependence on a few key suppliers.
Threat Of New Entrants
The threat of new entrants is high due to the growing demand for Cencora's products and the relatively low barriers to entry.
Intensity Of Rivalry
The intensity of rivalry in the industry is moderate, with several established players competing for market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 87.78% |
| Debt Cost | 5.96% |
| Equity Weight | 12.22% |
| Equity Cost | 6.29% |
| WACC | 6.00% |
| Leverage | 718.53% |
Cencora : Quality Control
Cencora passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CAH | Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
| MCK | McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AbbVie
A-Score
1-Year Total Return ->
🥈
Cencor
A-Score
1-Year Total Return ->
🥉
Cardinal Health
A-Score
1-Year Total Return ->
4
J&J
A-Score
1-Year Total Return ->
5
McKesson
A-Score
1-Year Total Return ->
6
